ClinicalTrials.gg
CompletedNCT00665327Updated Nov 18, 2014

Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia

A Phase 4 interventional study of Avelox (Moxifloxacin, BAY12-8039) and Levofloxacin in Pneumonia, sponsored by Bayer. Completed at 77 sites in 2 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2014-11-18.

Primary conditionCommunity-Acquired PneumoniaRegistry: PneumoniaReclassifiedWhy we changed it
Registry
Pneumonia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Community-Acquired Pneumonia
Why
  1. The study's title name Community-Acquired Pneumonia, a narrower term within Pneumonia.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
401
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Community-Acquired Pneumonia with a site in United States — 9 open to participants now, 12 under way, 3 of them phase 3. Community-Acquired Pneumonia · United States.

Enrollment
17th of 42
401 · median 190
Started
2002
with 1 other
Phase 4
7 of 52
3 open now
Registered
9th of 52
by date

Among the 52 studies in Community-Acquired Pneumonia with a site in United States, this one is the 17th largest by enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2002, is one of 7 in phase 4, and was the 9th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 78 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

9 of the 52 studies in Community-Acquired Pneumonia with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Community-Acquired Pneumonia with a site in United States, or all of them as a file.
02

Study summary

This study was to assess the safety of sequential intravenous (IV)/oral (PO) moxifloxacin (Avelox®) compared with sequential IV/PO levofloxacin (Levaquin®) in the treatment of elderly subjects (aged \≥ 65 years) with community-acquired pneumonia (CAP) who required initial IV therapy. This study also included an assessment of the clinical and bacteriologic effectiveness of both drugs.

03

Conditions studied

  • Pneumonia

Browse trials for

Keywords

  • Community Acquired Pneumonia
  • Pneumonia,
  • CAP
04

In context

Community-Acquired Pneumonia Reclassified

325 studies on the registry are indexed under Community-Acquired Pneumonia; 78 are open to participants now.

This study's enrollment of 401 is above the median of 246 across 196 interventional studies indexed under Community-Acquired Pneumonia.

Browse Community-Acquired Pneumonia studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Compared within Community-Acquired Pneumonia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pneumonia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of radiological evidence of a new or progressive infiltrate(s) consistent with bacterial pneumonia and at least 2 of the following:
  • Productive cough with purulent or mucopurulent sputum/tracheobronchial secretions or change in the character of sputum (increased volume or purulence)
  • Dyspnea or tachypnea
  • Rigors or chills- Pleuritic chest pain
  • Auscultatory findings on pulmonary examination of rales/crackles and/or evidence of pulmonary consolidation- Fever or hypothermia
  • White blood cell count >/= 10000/mm3 or >/= 15% immature neutrophils, regardless of the peripheral WBC count, or leukopenia with total WBC count \< 4500/mm3

Exclusion criteria

Exclusion Criteria:

  • Known to fluoroquinolones- Presence of end-organ damage or shock with need for vasopressors for > 4 hours at the time of study entry
  • Need for mechanical ventilation at study entry
  • Implanted cardiac defibrillator.- Significant bradycardia with heart rate \< 50 beats/minute.
  • Hospitalized for > 48 hours before developing pneumonia.
  • Systemic antibacterial therapy for more than 24 hours within 7 days of enrollment unless the patient was deemed a treatment failure after receiving greater than 72 hours of a non-fluoroquinolone antibiotic.
  • Co-existent disease considered likely to affect the outcome of the study (e.g. active lung cancer, connective tissue disease affecting the lungs, bronchiectasis).
  • Mechanical endobronchial obstruction (e.g. endobronchial tumor).
  • Known or suspected active tuberculosis or endemic fungal infection
  • Neutropenia ( \< 1000/Microliter).
  • Chronic treatment (equal or longer than 2 weeks) with known therapy (including treatment with > 15 mg/day of systemic prednisone or equivalent).
  • Patient with known infection and a \< 200/mm3 .
  • Known severe hepatic insufficiency .
  • Renal impairment with a baseline measured or calculated serum \< 20 mL/min. If a recent value for a 24 hour creatinine clearance is not available then the creatinine clearance should be calculated using the Cockcroft-Gault formula .
  • Known prolongation of the or use of Class IA or Class III antiarrhythmics (e.g., quinidine, procainamide, amiodarone, sotalol).
  • Uncorrected hypokalemia.
  • Previous history of tendinopathy with quinolones.
  • Previously entered in this study.- Participated in any clinical drug study within 4 weeks of screening.
  • Known or suspected concomitant bacterial infection requiring additional systemic antibacterial treatment.
  • Patients with a history of a hypersensitivity reaction to multivitamin infusion (MVI) or pre-existing hypervitaminosis.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
401 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Avelox (Moxifloxacin, BAY12-8039)

  • Active comparator
    Arm 2

    Drug: Levofloxacin

Interventions

  • Moxifloxacin 400 mg IV QD for a minimum of two doses followed by moxifloxacin 400 mg PO QD for a total treatment duration of 7 to 14 days

  • Levofloxacin 500 mg IV QD for a minimum of two doses followed by Levofloxacin 500 mg PO QD for a total treatment duration of 7 to 14 days. For patients who have a documented or calculated creatinine clearance of 20 - 49 ml/minute, the IV and PO dose of Levofloxacin will be a 500 mg loading dose followed by 250 mg QD for a total treatment duration of 7 to 14 days

07

What researchers measure

Primary outcomes

  1. Incidence of a composite safety end point (including cardiac arrest, sustained and non-sustained ventricular tachycardia), based on digital Holter ECG recordings

    Time frame: First 72 hours of study participation

Secondary outcomes

  1. Incidence of a composite safety end point (including atrial fibrillation sustained and unsustained supraventricular tachycardia, third degree AV block and long RR pauses), based on Holter

    Time frame: First 72 hours of study participation

  2. Adverse Events Collection

    Time frame: Up to 7-14 days post-therapy

  3. Clinical Response

    Time frame: Day 3-5 during treament, 7-14 days post-therapy

  4. Mortality attributable to pneumonia

    Time frame: 7-14 days post-therapy

  5. Bacteriological Response

    Time frame: 7-14 days post-therapy

  6. Overall cost of hospitalization

    Time frame: Up to 7-14 days post-therapy

08

Study locations

77 sites
  • Mobile, Alabama 36608-1798, United States
  • Tucson, Arizona 85723, United States
  • Tucson, Arizona 85724, United States
  • Brea, California 92821-3075, United States
  • Fullerton, California 92835-3800, United States
  • La Jolla, California 92093, United States
  • Madera, California 93637, United States
  • Bridgeport, Connecticut 06610, United States
  • Farmington, Connecticut 06030, United States
  • Stamford, Connecticut 06902-3628, United States
  • Brandon, Florida 33511, United States
  • Jacksonville, Florida 32209, United States
  • Orlando, Florida 32806-2093, United States
  • Sarasota, Florida 34239, United States
  • Tampa, Florida 33606-3508, United States
  • Austell, Georgia 30106-8116, United States
  • Blue Ridge, Georgia 30513, United States
  • Columbus, Georgia 31902, United States
  • Fort Gordon, Georgia 30905, United States
  • Marietta, Georgia 30060, United States
  • Honolulu, Hawaii 96817, United States
  • Coeur d'Alene, Idaho 83814-4487, United States
  • Elk Grove Village, Illinois 60007, United States
  • Springfield, Illinois 62703, United States
  • Fort Wayne, Indiana 46802-1493, United States
  • Indianapolis, Indiana 46202-2879, United States
  • Indianapolis, Indiana 46280, United States
  • Lexington, Kentucky 40536, United States
  • New Orleans, Louisiana 70112, United States
  • New Orleans, Louisiana 70122, United States
  • New Orleans, Louisiana 70127-3154, United States
  • Shreveport, Louisiana 71130-4228, United States
  • Cumberland, Maryland 21502, United States
  • Kalamazoo, Michigan 49048-1666, United States
  • Royal Oak, Michigan 48073-6769, United States
  • Duluth, Minnesota 55805-1984, United States
  • Columbia, Missouri 65212, United States
  • St. Louis, Missouri 63110-1094, United States
  • Anaconda, Montana 59711-2718, United States
  • Omaha, Nebraska 68105, United States
  • Holmdel, New Jersey 07733, United States
  • Neptune, New Jersey 07753, United States
  • Newark, New Jersey 07712-2027, United States
  • Albany, New York 12208-3473, United States
  • Johnson City, New York 13790, United States
  • Kingston, New York 12401, United States
  • Manhasset, New York 11030-3876, United States
  • Mineola, New York 11501, United States
  • New York, New York 10016-9198, United States
  • New York, New York 10029, United States
  • Syracuse, New York 13210-2399, United States
  • Chapel Hill, North Carolina 27599-7065, United States
  • Elizabeth City, North Carolina 27909, United States
  • Winston-Salem, North Carolina 27103, United States
  • Winston-Salem, North Carolina 27157, United States
  • Akron, Ohio 44304, United States
  • Columbus, Ohio 43214-3998, United States
  • Dayton, Ohio 45428, United States
  • Lima, Ohio 45801, United States
  • Tulsa, Oklahoma 74136-1902, United States
  • Allentown, Pennsylvania 18102, United States
  • Beaver, Pennsylvania 15009, United States
  • Hershey, Pennsylvania 17033-0850, United States
  • Philadelphia, Pennsylvania 19102, United States
  • Summerville, South Carolina 29485, United States
  • Jackson, Tennessee 38301-3855, United States
  • Knoxville, Tennessee 37920, United States
  • Memphis, Tennessee 38104, United States
  • El Paso, Texas 79905-2709, United States
  • San Antonio, Texas 78217-0156, United States
  • San Antonio, Texas 78229, United States
  • San Antonio, Texas 78236-5300, United States
  • San Antonio, Texas 78284-5799, United States
  • Salt Lake City, Utah 84102, United States
  • Lynchburg, Virginia 24501-1109, United States
  • Norfolk, Virginia 23507, United States
  • San Juan, 00921-3201, Puerto Rico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002, a primary completion of Apr 2004 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2008
First posted
Apr 23, 2008
Start
Nov 2002
Primary completionActual
Apr 2004
CompletionActual
Apr 2004
Last update
Nov 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00665327
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 23, 2008
Start date
Nov 2002
Primary completion
Apr 2004
Completion
Apr 2004
Last update
Nov 18, 2014

Study contacts

Bayer Study Director
study director · Bayer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion